

FINAL RESUME ON THE RESEARCH UNIT:
Integrative Tumour Immunology and Genetic
Oncology (INTIM)

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:

Université Paris-Sud

Institut National de la Santé et de la Recherche
Médicale – INSERM

Centre de Lutte Contre le Cancer de Villejuif -
Institut Gustave Roussy

EVALUATION CAMPAIGN 2018-2019
GROUP E



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the experts committee²:

Sophie Lucas, Chairwoman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data provided by laboratories and supervising bodies in the unit's application and in the Excel files "Données du contrat en cours" and "Données du prochain contrat".

UNIT PRESENTATION

Unit name:	Integrative Tumour Immunology and Genetic Oncology
Unit acronym:	INTIM
Requested label:	UMR
Application type:	Renewal
Current number:	1186
Head of the unit (2018-2019):	Ms Fathia MAMI-CHOUAIB
Project leader (2020-2024):	Ms Fathia MAMI-CHOUAIB
Number of themes:	2

EXPERTS COMMITTEE MEMBERS

Chair:	Ms Sophie LUCAS, Université catholique de Louvain, Belgium
Experts:	Ms Sophie DUCHEZ, CNRS/Institut Universitaire d'Hématologie (supporting personnel) Mr Nicolas FAZILLEAU, CHU Purpan (representative of Inserm CSS) Mr Dietrich KABELITZ, University Medical Center Schleswig-Holstein, Germany Mr Laurent MARTINY, Université de Reims Champagne-Ardenne (representative of CNU)

HCÉRES REPRESENTATIVE

Ms Sophie EZINE

REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Mr Étienne AUGE, Université Paris-Sud

Mr David BOUCARD, Gustave Roussy

Ms Guila CARRARA, Inserm

Christine CHOMIENNE, Inserm

Mr Laurent DELVA, Inserm

Mr Marc HUMBERT, Université Paris-Sud

Ms Laurence PARMENTIER, Inserm

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The research unit UMR1186 "Integrative Tumor Immunology and Immunotherapy" was created in 2015 by Ms Fathia Mami-Chouaib under the patronage of INSERM (Institut National de la Santé et de la Recherche Médicale), Paris 11 University, the Gustave Roussy Institute and the EPHE (École Pratique des Hautes Études). It is the continuation of a pre-existing dynamic research unit, initially named UMR487 "Cytokines and Tumor Immunology" (created by Mr Salem Chouaib, running from 1998-2004), then named UMR753 "Human tumor Immunology: cytotoxic effector – tumoral system interactions" (directed also by Mr Salem Chouaib, and running from 2005-2014).

The research unit is located at the "Institut de Cancérologie Gustave Roussy", in the Paris area.

MANAGEMENT TEAM

The unit UMR1186 is headed by Ms Fathia Mami-Chouaib.

HCÉRES NOMENCLATURE

SVE3_4

SCIENTIFIC DOMAIN

Research at UMR1186 is dedicated to studying antitumor immune responses, the tumor microenvironment and oncogenesis in the context of lung cancer, melanoma and renal cell carcinoma (RCC). It encompasses both fundamental and translational research.

UNIT WORKFORCE

	Unit workforce	
	INTIM	
Active staff	Number 30/06/2018	Number 01/01/2020
Full professors and similar positions	1	0
Assistant professors and similar positions	3	0
Full time research directors (Directeurs de recherche) and similar positions	2	2
Full time research associates (Chargés de recherche) and similar positions	2	3
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	1	1
High school teachers	0	0

Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	8	6
Permanent staff	17	12
Non-permanent professors and associate professors, including emeritus	1	
Non-permanent full time scientists, including emeritus, post-docs	1	
<i>PhD Students</i>	9	
Non-permanent supporting personnel	2	
Non-permanent staff	13	
Total	30	12

GLOBAL ASSESSMENT OF THE UNIT

The unit has made significant original contributions to the fields of antitumor immunity and the tumour microenvironment. Overall, its scientific outputs and activities, academic collaborations, and reputation are excellent. The unit has been outstanding in its interactions with the non-academic world, as evidenced by the number of patents filed or granted, its participation to numerous clinical trials and creation of a start up. Team members have trained numerous students, are involved in the teaching of Master programs and a series of highly specialised courses and educational programs in onco-immunology, both in France and abroad. To foster high quality research while maintaining fund raising levels above a critical mass, it will be essential to identify the next generation of scientific leaders, as two PIs will be emeritus in the next mandate. The new projects imply multidisciplinary interactions, at the interface between biomedical and clinical sciences, with highly integrated approaches to develop more effective immunotherapies of cancer.

In conclusion, the committee's assessment of the unit is excellent.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)